An Off-Target Nucleostemin RNAi Inhibits Growth in Human Glioblastoma-Derived Cancer Stem Cells

Glioblastomas (GBM) may contain a variable proportion of active cancer stem cells (CSCs) capable of self-renewal, of aggregating into CD133+ neurospheres, and to develop intracranial tumors that phenocopy the original ones. We hypothesized that nucleostemin may contribute to cancer stem cell biology as these cells share characteristics with normal stem cells. Here we report that nucleostemin is expressed in GBM-CSCs isolated from patient samples, and that its expression, conversely to what it has been described for ordinary stem cells, does not disappear when cells are differentiated. The significance of nucleostemin expression in CSCs was addressed by targeting the corresponding mRNA using lentivirally transduced short hairpin RNA (shRNA). In doing so, we found an off-target nucleostemin RNAi (shRNA22) that abolishes proliferation and induces apoptosis in GBM-CSCs. Furthermore, in the presence of shRNA22, GBM-CSCs failed to form neurospheres in vitro or grow on soft agar. When these cells are xenotransplanted into the brains of nude rats, tumor development is significantly delayed. Attempts were made to identify the primary target/s of shRNA22, suggesting a transcription factor involved in one of the MAP-kinases signaling-pathways or multiple targets. The use of this shRNA may contribute to develop new therapeutic approaches for this incurable type of brain tumor.

[1]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[2]  Charles G. Gross,et al.  Neurogenesis in the adult brain: death of a dogma , 2000, Nature Reviews Neuroscience.

[3]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[4]  R. McKay,et al.  A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. , 2002, Genes & development.

[5]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[8]  L. Yajun,et al.  The effect of knocking-down nucleostemin gene expression on the in vitro proliferation and in vivo tumorigenesis of HeLa cells. , 2004, Journal of experimental & clinical cancer research : CR.

[9]  D. Elder,et al.  A tumorigenic subpopulation with stem cell properties in melanomas. , 2005, Cancer research.

[10]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[11]  Tomoyuki Yamada,et al.  dsCheck: highly sensitive off-target search software for double-stranded RNA-mediated RNA interference , 2005, Nucleic Acids Res..

[12]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[13]  Xiaoan Ruan,et al.  siRNA-mediated off-target gene silencing triggered by a 7 nt complementation , 2005, Nucleic acids research.

[14]  Nir Hacohen,et al.  Minimizing the risk of reporting false positives in large-scale RNAi screens , 2006, Nature Methods.

[15]  R. Y. Tsai,et al.  Nucleostemin Delays Cellular Senescence and Negatively Regulates TRF1 Protein Stability , 2006, Molecular and Cellular Biology.

[16]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[17]  Peter T Masiakos,et al.  Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[19]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[20]  Sean J. Morrison,et al.  Asymmetric and symmetric stem-cell divisions in development and cancer , 2006, Nature.

[21]  L. Lim,et al.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. , 2006, RNA.

[22]  A. Hollander,et al.  Nucleostemin Is a Marker of Proliferating Stromal Stem Cells in Adult Human Bone Marrow , 2006, Stem cells.

[23]  W. Wurst,et al.  Evolutionarily Conserved Role of Nucleostemin: Controlling Proliferation of Stem/Progenitor Cells during Early Vertebrate Development , 2006, Molecular and Cellular Biology.

[24]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[25]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[26]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[27]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[28]  Hanhui Ma,et al.  Depletion of the nucleolar protein nucleostemin causes G1 cell cycle arrest via the p53 pathway. , 2007, Molecular biology of the cell.

[29]  M. Dai,et al.  Aberrant Expression of Nucleostemin Activates p53 and Induces Cell Cycle Arrest via Inhibition of MDM2 , 2008, Molecular and Cellular Biology.

[30]  M. Matin,et al.  Knocking‐down the expression of nucleostemin significantly decreases rate of proliferation of rat bone marrow stromal stem cells in an apparently p53‐independent manner , 2008, Cell proliferation.

[31]  K. Wong,et al.  Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133+ Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma , 2008, Stem cells.

[32]  M. Krause,et al.  Exploring the role of cancer stem cells in radioresistance , 2008, Nature Reviews Cancer.

[33]  M. Biffoni,et al.  Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.

[34]  Yuer Zhang,et al.  Expression of nucleostemin in prostate cancer and its effect on the proliferation of PC-3 cells. , 2008, Chinese medical journal.

[35]  R. Weinberg,et al.  Cancer stem cells: mirage or reality? , 2009, Nature Medicine.

[36]  L. Romanova,et al.  Novel Role of Nucleostemin in the Maintenance of Nucleolar Architecture and Integrity of Small Nucleolar Ribonucleoproteins and the Telomerase Complex* , 2009, The Journal of Biological Chemistry.

[37]  L. Romanova,et al.  Critical Role of Nucleostemin in Pre-rRNA Processing* , 2009, Journal of Biological Chemistry.

[38]  A. Schnerch,et al.  Characterization of human embryonic stem cells with features of neoplastic progression , 2009, Nature Biotechnology.

[39]  Khalid Shah,et al.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. , 2009, Cancer research.

[40]  E. Holland,et al.  Brain tumor treatment increases the number of cancer stem-like cells , 2009, Expert review of neurotherapeutics.

[41]  Y. Okazaki,et al.  Differential Requirement for Nucleostemin in Embryonic Stem Cell and Neural Stem Cell Viability , 2009, Stem cells.

[42]  W. Schulz,et al.  Differential effects of Nucleostemin suppression on cell cycle arrest and apoptosis in the bladder cancer cell lines 5637 and SW1710 , 2009, Cell proliferation.

[43]  Lingjun Meng,et al.  Cancer esearch or and Stem Cell Biology or-Initiating Function of Nucleostemin-Enriched R mary Tumor Cells in , 2010 .

[44]  P. Linsley,et al.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.

[45]  K. Black,et al.  T Cells Enhance Stem-Like Properties and Conditional Malignancy in Gliomas , 2010, PloS one.

[46]  Y. Atlasi,et al.  Differential expression of nucleostemin, a stem cell marker, and its variants in different types of brain tumors , 2010, Molecular carcinogenesis.

[47]  Jing Wang,et al.  Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. , 2011, Neuro-oncology.

[48]  Chris Sander,et al.  Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2 , 2011, Silence.